Cargando…

Randomized Controlled Trial of a Home‐Based Walking Program to Reduce Moderate to Severe Aromatase Inhibitor‐Associated Arthralgia in Breast Cancer Survivors

BACKGROUND. In postmenopausal women diagnosed with breast cancer (BC), most BC tumors are hormone receptor positive and guidelines recommend adjuvant endocrine therapy that includes an aromatase inhibitor (AI). This study investigates the impact of a 6‐week, home‐based, self‐directed walking program...

Descripción completa

Detalles Bibliográficos
Autores principales: Nyrop, Kirsten A., Callahan, Leigh F., Cleveland, Rebecca J., Arbeeva, Liubov L., Hackney, Betsy S., Muss, Hyman B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5634775/
https://www.ncbi.nlm.nih.gov/pubmed/28698390
http://dx.doi.org/10.1634/theoncologist.2017-0174
_version_ 1783270159037759488
author Nyrop, Kirsten A.
Callahan, Leigh F.
Cleveland, Rebecca J.
Arbeeva, Liubov L.
Hackney, Betsy S.
Muss, Hyman B.
author_facet Nyrop, Kirsten A.
Callahan, Leigh F.
Cleveland, Rebecca J.
Arbeeva, Liubov L.
Hackney, Betsy S.
Muss, Hyman B.
author_sort Nyrop, Kirsten A.
collection PubMed
description BACKGROUND. In postmenopausal women diagnosed with breast cancer (BC), most BC tumors are hormone receptor positive and guidelines recommend adjuvant endocrine therapy that includes an aromatase inhibitor (AI). This study investigates the impact of a 6‐week, home‐based, self‐directed walking program on the commonly reported side effect of AI‐associated arthralgia (AIAA). MATERIALS AND METHODS. In this phase II trial, consented BC patients were randomized to walking Intervention (n = 31) or Wait List Control (WLC; n = 31). Eligibility criteria included: stage 0–III BC, on AI for at least 4 weeks, ≥3 on a 5‐point scale inquiring about joint symptom intensity “at its worst,” and exercising ≤150 minutes per week. Outcomes were self‐reported joint symptoms and psychosocial measures. Analyses comparing Intervention and WLC groups were conducted on an intention‐to‐treat basis to assess intervention impact at 6 weeks (postintervention) and at 6‐months follow‐up. Adjusted means were calculated to assess differences in two groups. RESULTS. In our final sample (n = 62), mean age was 64 years, 74% were white, and 63% had a body mass index of 30 or higher. At postintervention, Intervention group participants reported significantly increased walking minutes per week, reduced stiffness, less difficulty with activities of daily living (ADL), and less perceived helplessness in managing joint symptoms. At 6‐months follow‐up (postwalking period in both Intervention and WLC), walking minutes per week had decreased significantly; however, improvements in stiffness and difficulty with ADLs were maintained. CONCLUSION. This study adds to the growing evidence base suggesting exercise as a safe alternative or adjunct to medications for the management of AIAA. IMPLICATIONS FOR PRACTICE. Breast cancer survivors whose adjuvant endocrine treatment includes an aromatase inhibitor (AI) often experience the side effect of AI‐associated arthralgia (AIAA). This study investigates the impact of a 6‐week, home‐based, self‐directed walking program in the management of AIAA. Compared with Wait List Control, women in the Intervention group reported significantly increased walking minutes per week, reduced stiffness, less difficulty with activities of daily living, and less perceived helplessness in managing joint symptoms. This study adds to the growing evidence base suggesting exercise as a safe alternative or adjunct to medications for the management of AIAA.
format Online
Article
Text
id pubmed-5634775
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher AlphaMed Press
record_format MEDLINE/PubMed
spelling pubmed-56347752018-04-01 Randomized Controlled Trial of a Home‐Based Walking Program to Reduce Moderate to Severe Aromatase Inhibitor‐Associated Arthralgia in Breast Cancer Survivors Nyrop, Kirsten A. Callahan, Leigh F. Cleveland, Rebecca J. Arbeeva, Liubov L. Hackney, Betsy S. Muss, Hyman B. Oncologist Breast Cancer BACKGROUND. In postmenopausal women diagnosed with breast cancer (BC), most BC tumors are hormone receptor positive and guidelines recommend adjuvant endocrine therapy that includes an aromatase inhibitor (AI). This study investigates the impact of a 6‐week, home‐based, self‐directed walking program on the commonly reported side effect of AI‐associated arthralgia (AIAA). MATERIALS AND METHODS. In this phase II trial, consented BC patients were randomized to walking Intervention (n = 31) or Wait List Control (WLC; n = 31). Eligibility criteria included: stage 0–III BC, on AI for at least 4 weeks, ≥3 on a 5‐point scale inquiring about joint symptom intensity “at its worst,” and exercising ≤150 minutes per week. Outcomes were self‐reported joint symptoms and psychosocial measures. Analyses comparing Intervention and WLC groups were conducted on an intention‐to‐treat basis to assess intervention impact at 6 weeks (postintervention) and at 6‐months follow‐up. Adjusted means were calculated to assess differences in two groups. RESULTS. In our final sample (n = 62), mean age was 64 years, 74% were white, and 63% had a body mass index of 30 or higher. At postintervention, Intervention group participants reported significantly increased walking minutes per week, reduced stiffness, less difficulty with activities of daily living (ADL), and less perceived helplessness in managing joint symptoms. At 6‐months follow‐up (postwalking period in both Intervention and WLC), walking minutes per week had decreased significantly; however, improvements in stiffness and difficulty with ADLs were maintained. CONCLUSION. This study adds to the growing evidence base suggesting exercise as a safe alternative or adjunct to medications for the management of AIAA. IMPLICATIONS FOR PRACTICE. Breast cancer survivors whose adjuvant endocrine treatment includes an aromatase inhibitor (AI) often experience the side effect of AI‐associated arthralgia (AIAA). This study investigates the impact of a 6‐week, home‐based, self‐directed walking program in the management of AIAA. Compared with Wait List Control, women in the Intervention group reported significantly increased walking minutes per week, reduced stiffness, less difficulty with activities of daily living, and less perceived helplessness in managing joint symptoms. This study adds to the growing evidence base suggesting exercise as a safe alternative or adjunct to medications for the management of AIAA. AlphaMed Press 2017-07-11 2017-10 /pmc/articles/PMC5634775/ /pubmed/28698390 http://dx.doi.org/10.1634/theoncologist.2017-0174 Text en © AlphaMed Press 2017
spellingShingle Breast Cancer
Nyrop, Kirsten A.
Callahan, Leigh F.
Cleveland, Rebecca J.
Arbeeva, Liubov L.
Hackney, Betsy S.
Muss, Hyman B.
Randomized Controlled Trial of a Home‐Based Walking Program to Reduce Moderate to Severe Aromatase Inhibitor‐Associated Arthralgia in Breast Cancer Survivors
title Randomized Controlled Trial of a Home‐Based Walking Program to Reduce Moderate to Severe Aromatase Inhibitor‐Associated Arthralgia in Breast Cancer Survivors
title_full Randomized Controlled Trial of a Home‐Based Walking Program to Reduce Moderate to Severe Aromatase Inhibitor‐Associated Arthralgia in Breast Cancer Survivors
title_fullStr Randomized Controlled Trial of a Home‐Based Walking Program to Reduce Moderate to Severe Aromatase Inhibitor‐Associated Arthralgia in Breast Cancer Survivors
title_full_unstemmed Randomized Controlled Trial of a Home‐Based Walking Program to Reduce Moderate to Severe Aromatase Inhibitor‐Associated Arthralgia in Breast Cancer Survivors
title_short Randomized Controlled Trial of a Home‐Based Walking Program to Reduce Moderate to Severe Aromatase Inhibitor‐Associated Arthralgia in Breast Cancer Survivors
title_sort randomized controlled trial of a home‐based walking program to reduce moderate to severe aromatase inhibitor‐associated arthralgia in breast cancer survivors
topic Breast Cancer
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5634775/
https://www.ncbi.nlm.nih.gov/pubmed/28698390
http://dx.doi.org/10.1634/theoncologist.2017-0174
work_keys_str_mv AT nyropkirstena randomizedcontrolledtrialofahomebasedwalkingprogramtoreducemoderatetoseverearomataseinhibitorassociatedarthralgiainbreastcancersurvivors
AT callahanleighf randomizedcontrolledtrialofahomebasedwalkingprogramtoreducemoderatetoseverearomataseinhibitorassociatedarthralgiainbreastcancersurvivors
AT clevelandrebeccaj randomizedcontrolledtrialofahomebasedwalkingprogramtoreducemoderatetoseverearomataseinhibitorassociatedarthralgiainbreastcancersurvivors
AT arbeevaliubovl randomizedcontrolledtrialofahomebasedwalkingprogramtoreducemoderatetoseverearomataseinhibitorassociatedarthralgiainbreastcancersurvivors
AT hackneybetsys randomizedcontrolledtrialofahomebasedwalkingprogramtoreducemoderatetoseverearomataseinhibitorassociatedarthralgiainbreastcancersurvivors
AT musshymanb randomizedcontrolledtrialofahomebasedwalkingprogramtoreducemoderatetoseverearomataseinhibitorassociatedarthralgiainbreastcancersurvivors